Multiple myeloma (MM) is an incurable malignancy of terminally differentiated B-lymphoid cells. Here, we investigate the role of Fas apoptosis inhibitory molecule (FAIM) in MM. We demonstrate that insulin-like growth factor 1 (IGF-1) treatment upregulated FAIM expression in MM cells in a dose-dependent manner. Silencing of FAIM expression attenuates Akt signaling downstream of IGF-1 and compromises the viability of MM cells. We further showed that IGF-1 stimulation of MM cells leads to enhanced expression of IRF4, a known 'addictive' factor for MM. This upregulation of IRF4 expression by IGF-1 treatment of MM cells is abrogated when FAIM expression is silenced or Akt activation is inhibited. Thus, FAIM modulates IGF-1-induced Akt activation and IRF4 expression and has a role in MM cell survival. Consistent with these findings, FAIM expression is shown to be higher in plasma cells of symptomatic MM patients compared with normal individuals or patients with premalignant conditions. Moreover, a higher level of FAIM expression is shown to correlate with poorer survival outcomes of newly diagnosed MM patients treated with stem cell transplantation or relapsed MM patients treated in clinical trials with Bortezomib. Thus taken together, our study reveals a novel, as well as clinically relevant role for FAIM in MM.
INTRODUCTION
Multiple myeloma (MM) is an incurable hematological malignancy arising from the transformation of terminally differentiated antibody-producing cells. 1, 2 It is characterized at the cellular level by uncontrolled accumulation of monoclonal plasma cells in the bone marrow where cells receive signals from the tumor microenvironment to survive and proliferate. 3 The disease clinical manifestations include excessive production of immunoglobulins, anemia, lytic bone lesions, hypercalcemia and renal failure. 4 Current standard treatment of MM includes high-dose chemotherapy 5 and stem cell transplantation 6, 7 or treatment with chemical agents with broad or undefined specificity such as the proteasome inhibitor bortezomib 8, 9 and the thalidomide analog lenalidomide. 10, 11 These treatments extend patients' lifespan but are usually non-curative and hence there is a need for a way to identify patients amenable to current standard treatments or in need of new therapeutic approaches.
The pathogenesis of MM is only beginning to be understood. Several chromosome translocations involving the juxtapositioning of genes (such as those encoding CCDN1, CCDN3, MAF and others) to the immunoglobulin heavy chain locus have been described. 12 The transcription factor IRF4, which has a key role in plasma cell differentiation, has also been documented to be translocated to the immunoglobulin heavy chain locus in a few MM cell lines and patient samples. 13 Furthermore, the activation of MYC, KRAS, NRAS, FGFR3 and NF-kB signaling pathways are also thought to contribute to the malignant progression of MM.
14 More recently, IRF4 had been identified as key to the survival of MM cells regardless of their gene mutation status as modest reduction in its expression level could severely compromised MM cell viability. 15 Thus, IRF4 or components of IRF4 signaling pathway or molecules mediating IRF4 expression could present excellent opportunities for new therapeutic drug discovery in MM.
Overexpression of IRF4 in the BaF3 cell line leads to the increased expression of several target genes, one of which encodes for FAIM or Fas apoptosis inhibitory molecule. 16 FAIM was first cloned from antigen-activated B cells and shown to protect these cells from activation-induced cell death. 17 It is ubiquitously expressed and well conserved in evolution although it bears no homology to any known protein. FAIM had been shown to lead to NF-kB activation and prolonged the lifespan of neuronal cells in culture. 18 More recently, our group demonstrated that FAIM had a critical role in protecting developing thymocytes from apoptosis and hepatocytes and mice from injury-induced death. 19, 20 Furthermore, gene-profiling study had indicated that FAIM expression was significantly downregulated in human pancreatic cancer cells upon their treatment with histone deacetylase inhibitor, which induced the apoptosis of these cells. 21 Hence, FAIM appears to have a critical role in the survival of numerous cell types and in pancreatic tumor. However, a role for FAIM in MM cell survival has not been explored or investigated.
We hypothesize that FAIM might have a physiological role in MM given that IRF4 has a pivotal role in the survival of MM cells. 15 Moreover, FAIM was shown recently to enhance CD40 signalling 22 and augment in a feed forward manner, IRF4 expression in B cells. 23 Since CD40 signaling and IRF4 and NF-kB activation are known to contribute to MM pathology [24] [25] [26] [27] it is highly plausible that FAIM could also have a critical role in MM. In this study, we demonstrated that IGF-1 stimulation leads to the upregulation of FAIM and IRF4 expression in MM cells. In addition, we showed that IGF-1 induction of Akt activation and IRF4 expression is mediated by FAIM, and FAIM has a role in MM cell viability. More importantly, FAIM expression was found to be highly expressed in symptomatic MM patients compared with normal or premalignant individuals. A higher level of FAIM expression was also found to correlate with poorer survival outcomes for MM patients. Thus our data suggest that FAIM could be used as a potential biomarker to identify MM patients with poor prognoses with current standard treatments, as well as a therapeutic target in these patients.
SUBJECTS AND METHODS Reagents
Cell culture media RPMI1640, optimal medium and penicillin-streptomycin were purchased from GIBCO BRL, Life Technologies (Bleiswijk, The Netherlands). Fetal bovine serum (defined) was from Thermo Scientific (Rockford, IL, USA). Anti-human IGF-1 antibody, human cytokines, IGF-1, interleukin (IL)-6, vascular endothelial growth factor and IL-1b were from PeproTech Inc (Rocky Hill, NJ, USA). Human FAIM-specific and control small interfering RNAs (siRNAs) and antibodies used for western blot analyses in this study including anti-b-actin (N-21), anti-IRF4 (M-17), anti-phosphoAkt1/ 2/3 (Thr308), goat anti-mouse IgG-horseradish peroxidase, donkey antigoat IgG-horseradish peroxidase and goat anti-rabbit IgG-horseradish peroxidase were purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA, USA). Anti-Mcl-1 and anti-Blimp-1 antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). The anti-FAIM rabbit polyclonal antibody was raised in-house against the full length protein of mouse FAIM. 19, 20 The Akt inhibitor (1, 3-Dihydro-1-(1-((4-(6-phenyl-1H-imidazo [4, 5-g] quinoxalin-7-yl) phenyl) methyl)-4-piperidinyl)-2H-benzimidazol-2-one trifluoroacetate salt) was purchased from Sigma-Aldrich (St Louis, MO, USA). Annexin V apoptosis detection kit was purchased from BD Pharmingen (San Diego, CA, USA). The transfection reagent Lipofectamine 2000 was purchased from Life Technologies (Carlsbad, CA, USA).
MM cell culture
The MM cell lines OPM2, RPMI8226, XG-7, XG-6, OCIMY5, KMS-12BM, U266, H929 and KMS-28BM were cultured at 37 1C and 5% CO 2 in RPMI1640 medium supplemented with 2.05 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum. XG-7, XG-6 and OCIMY5 cells were additionally cultured with 2 ng/ml human IL-6 and H929 cells were additionally supplied with 50 mM b-mercaptoethanol.
Western blot analyses of protein expression
Whole-cell extracts were prepared using lysis buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Igepal CA-630, 0.2 mM Na 3 VO 4 and a protease inhibitor cocktail (Roche, Basel, Switzerland)). Protein concentration was measured by a colorimetric assay (Bio-Rad Laboratories, Hemel Hempstead, Hertfordshire, UK) and equal amount of proteins were loaded onto SDS gels. After transfer to PVDF (polyvinylidene difluoride) membranes, the proteins were probed with primary antibodies (1 mg/ml), followed by horseradish peroxidase-conjugated secondary antibodies, washed and visualized with SuperSignal West Pico/Dura chemiluminescent substrate (Pierce, Rockford, IL, USA). The blots were reprobed with a b-actin-specific antibody to provide for loading controls. Cell viability assays MM cell viability was analyzed using Annexin V apoptosis detection kit (BD Pharmingen). Briefly, 0.1 Â 10 6 /ml cells were harvested, washed once with cold phosphate-buffered saline, and resuspended in 1 Â annexin-binding buffer. Cell survival was determined by annexin V-fluorescein isothiocyanate/propidium iodide double-negative staining. Samples were analyzed on fluorescence-activated cell sorting Calibur using the software program CellQuest (both from Becton Dickinson, Franklin Lakes, NJ, USA). All experiments were performed in triplicate.
FAIM expression profiling in clinical data sets and analyses of overall survival of MM patients Examination of FAIM mRNA expression in normal and malignant plasma cells was performed using publicly available gene expression data set (GEO accession number GSE 6477). 28 For survival analysis, two different data sets of patients involved in clinical trials were used. Namely those participating in the total therapy studies (GEO Accession number GSE2658) and those involved in the Apex Trial (GEO Accession number GSE9782). The distribution for overall survival was estimated using the method of Kaplan and Meier. Survival was compared using the log-rank test. The Mann-Whitney U-test is used for comparision of FAIM expression across the clinical subtypes (monoclonal gammopathy of undetermined significance, smoldering MM and MM) and normal plasma cells. P-values of o0.05 is considered significant.
Statistical analysis
All experiments in this study were performed at least three times. Data are presented as mean ± s.e.m. Statistical comparison of the data was performed using Student's t-test. Group difference with Po0.05 was considered statistically significant.
RESULTS
FAIM is required for MM cell survival and expression of critical MM genes To determine if FAIM has any relevance in MM physiology, we first studied its expression in a panel of MM cell lines. Our western blot analyses, as shown in Figure 1a , indicated that FAIM is expressed in all MM cell lines tested, albeit at different levels. As FAIM is ubiquitously expressed at basal level in MM cells, we proceeded to knock down its expression in representative MM cells using siRNA technology and later, studied the effect of FAIM knockdown in MM cells using a serum withdrawal-induced cell death model. As shown in Figure 1b , the introduction of FAIM-specific siRNA led to greatly reduced level of FAIM protein expression in various MM cell lines (RPMI8226, U266, KMS-12BM and H929) tested as compared with the introduction of control siRNA into these cells. When control and FAIM-knockdown cells were starved for 48 h, it was apparent that FAIM-knockdown MM cells had significantly reduced viability and did not survive as well as control cells in culture ( Figure 1c ). Compared with control siRNA-transfected cells, FAIM siRNA-transfected RPMI8226, U266, KMS-12BM and H929 cells had 24.7%, 34.2%, 25.7% and 16.7% decrease in cell viability, respectively. These results suggested that FAIM expression might be important for MM cell survival.
A number of critical genes have been associated with MM cell survival and physiology. Among them is the transcription factor Blimp-1 that is important for plasma cell survival and persistence. 29 The cell survival gene Mcl-1 has also been shown to be essential for MM cell viability. 30 Hence, we examined the level of expression of these proteins in RPMI8226 and U266 cells transfected with control or FAIM-specific siRNAs (Figure 1d ). showing the greatest induction. Another growth factor for MM cells is IL-6. 33 Again, we demonstrated that OPM2, RPMI8226 and U266 MM cells could upregulate FAIM when treated with this inflammatory cytokine (Figure 2b ). Last but not least, we stimulated the panel of MM cell lines with two additional factors vascular endothelial growth factor and IL-1b, and compared their ability to upregulate FAIM expression alongside IGF-1 and IL-6. It became apparent that IL-1b could hardly upregulate FAIM while vascular endothelial growth factor could induce a slightly higher level of FAIM expression only in OPM2 and KMS-12BM cells (Figure 2c) . Overall, IGF-1 and IL-6 are two growth factors that could consistently increase FAIM expression in MM cell lines, with IGF-1 being the most potent. Taken together, our data indicated that FAIM protein expression level could be further elevated in MM cells upon certain growth factor stimulation and suggested that FAIM could contribute in some manner toward MM survival and pathology. For our subsequent experiments, we would be using IGF-1 to stimulate MM cells as it consistently elicited the strongest upregulation of FAIM expression.
IGF-1 activation of Akt signaling is modulated by FAIM in MM cells
As FAIM expression could be further induced in MM cells upon their stimulation with growth factors, we were interested to examine the signaling pathway that FAIM could potentially mediate in IGF-1-treated MM cells. As FAIM knockdown compromised the survival of MM cells, we hypothesized that Akt signaling, which is known to mediate cell survival, might be affected. Previously, we had demonstrated that FAIM expression in T cells affected T-cell receptor-induced activation of Akt. 20 IGF-1 stimulation of MM cells is also known to activate Akt signaling. 34 Hence, we wonder if IGF-1-induced activation of Akt signaling in MM cells would be mediated via FAIM. To examine this possibility, we transfected XG-7 and RPMI8226 cells with control siRNA or FAIM-specific siRNA and examined their activation of Akt in the presence or absence of IGF-1 treatment. As shown in Figure 3a , IGF-1 treatment of control siRNA-transfected XG-7 and RPMI8226 cells led to increased FAIM expression over the basal state and also upregulated Akt activation as evidenced by enhanced phosphorylation of the threonine 308 residue of Akt. By contrast, FAIM upregulation in response to IGF-1 stimulation was prevented in FAIM siRNA-transfected XG-7 and RPMI8226 cells and correspondingly, the activation of Akt was also downmodulated. These data indicate that FAIM acts upstream of Akt and the level of FAIM expression affects the level of Akt activation in MM cells in response to IGF-1 signaling.
As IGF-1 is a growth and survival factor for MM cells, 31 we also monitored the survival of control siRNA and FAIM siRNAtransfected XG-7 and RPMI8226 cells in response to IGF-1 treatment. The data in Figure 3b depicted the percentage of viable cells in control siRNA-or FAIM siRNA-transfected samples with or without IGF-1 treatment. It was evident that IGF-1 treatment led to increase in cell viability (71.5% vs 46.3%) in control siRNA-transfected XG-7 cells. However, the ability of IGF-1 to enhance cell viability was significantly reduced in FAIM siRNAtransfected XG-7 cells (47.5% vs 40.7%). Similarly, IGF-1 was able to increase cell viability in control siRNA-transfected RPMI8226 cells (68.4% vs 50.7%). Again, this effect was significantly reduced when FAIM expression was downmodulated in FAIM siRNA-transfected RPMI8226 cells (42.4% vs 39%) (Figure 3b) . Thus, the level of FAIM expression affects IGF-1-induced activation of Akt and enhancement of MM cell viability.
IGF-1 signaling via FAIM and Akt mediates IRF4 expression in MM cells
The transcription factor IRF4 has been described to be an 'additive' factor for MM and its downmodulation impaired MM cell survival. 15 It has recently been reported that FAIM modulates IRF4 expression in murine B cell lines. 22 However, it has not yet been established if FAIM would mediate IRF4 in MM cells. To address this possibility, we transfected control or FAIM-specific siRNAs into RPMI8226 and U266 cells and examined their expression of IRF4. The knockdown of FAIM in these two cell lines was as shown previously in Figure 1b . As shown in Figure 4a , the introduction of FAIM siRNA led to a decrease in the basal Figure 4b , RPMI8226, XG-7, OPM2 and KMS-28BM cells all upregulated their expression of IRF4 upon IGF-1 stimulation and this occurred in a dose-dependent manner. These data indicated that IGF-1 could directly upregulate IRF4 expression in MM cells and further suggested that IGF-1 enhancement of MM cell survival could be explained in part by its ability to increase IRF4 expression. To definitively ascertain that IGF-1 could specifically induce IRF4 upregulation, we treated the samples with neutralizing anti-IGF-1 (5 mg/ml) antibodies 35 and found that the induction of FAIM and IRF4 expression by IGF-1 treatment was abolished (results not illustrated).
To examine if IGF-1 induction of IRF4 expression in MM cells also involves Akt signaling, we examined the upregulation of IRF4 expression in IGF-1-treated but Akt-inhibited RPMI8226, XG-7, OPM2 and KMS-28BM cells (Figure 4c) . Consistent with the above data, IGF-1 treatment could upregulate IRF4 expression in these cells. However, IGF-1 induction of IRF4 expression was dramatically decreased or curtailed when Akt signaling is inhibited in these cells. These data together indicate that IGF-1 treatment of MM cells could upregulate IRF4 and this upregulation occurs via Akt signaling.
Finally, we examined if IGF-1 induction of IRF4 expression in MM cells would occur via FAIM. To accomplish this, we examine MM cells whose FAIM expression was reduced by siRNA transfection (Figure 4d) . Indeed, concomitant with the reduction of FAIM expression, IGF-1 induction of IRF4 expression was also severely repressed in RPMI8226 cells that were transfected with FAIMspecific but not control siRNA.
Thus, the data in Figure 4 indicate the existence of an IGF-1-Akt-IRF4 signaling pathway in MM cells. This observation and those in Figure 3 indicating that FAIM acted upstream of Akt in IGF-1 signaling together suggest that IGF-1stimulation induced a FAIM-Akt-IRF4 signaling axis in MM cells.
Clinical and prognostic relevance of FAIM expression in MM cells
The in vitro data so far indicated that FAIM might indeed have a physiological role in MM. To better understand the relevance of FAIM in MM, we proceeded to examine its expression in normal and diseased tissues using a primary public gene expression data set. 36, 28 We investigated mRNA expression of FAIM in normal and malignant plasma cell samples from 15 healthy individuals and 147 patients with various plasma cell neoplasm. The latter include 22 cases of monoclonal gammopathy of undetermined significance, 24 smoldering MM and 101 symptomatic MM and of the 101 MM cases, 72 were newly diagnosed and 29 were relapsed cases. As shown in Figure 5 , FAIM expression level was found to be significantly increased in MM patients compared with normal individuals. More importantly, when compared with asymptomatic but malignant condition such as smoldering MM, the expression level of FAIM was again found to be higher for MM. Hence, FAIM appears to be aberrantly upregulated in MM.
To determine if FAIM has any prognostic relevance for MM, we examined the impact of FAIM expression levels on patient survival in two large clinical cohorts. 28 In a data set of 351 newly diagnosed myeloma patients treated with high-dose chemotherapy and stem cell transplantation in the total therapy protocol, 37 high expression of FAIM (higher than median expression) was associated with significantly shorter survival compared with low expression of FAIM (lower than median) (Figure 6a) . In a different clinical data set of relapsed patients treated in clinical trials with the proteasome inhibitor Velcade or Bortezomib, high FAIM expression was again correlated with poorer overall survival (Figure 6b ). However, we found that high FAIM expression was not an independent prognostic factor on multivariate analysis (data not shown). Nevertheless, the clinical data suggested that elevated FAIM expression is of some biological and clinical relevance.
DISCUSSION
We investigated the role of FAIM in MM and showed that its expression could be upregulated in MM cells by known MM growth factors, and in particular IGF-1 (Figure 2) . Moreover, we showed that IGF-1 stimulation of MM cells also led to the upregulation of IRF4 expression (Figure 4) , which had been shown to be an 'addictive' factor for MM. 15 This induction of IRF4 by IGF-1 in MM cells required FAIM expression and Akt activation, and we further showed that FAIM acts upstream of Akt in IGF-1 signaling in MM cells. Hence, taken together, we have defined a FAIM-Akt-IRF4 signaling axis downstream of IGF-1 signaling in MM cells. In view of the importance of IGF-1 signaling in the survival of myeloma cells 38 and the elevated expression of IGF-1R in high-risk myeloma, 36 this novel axis involving FAIM and IRF4 may be important in the biology of myeloma, as well as its interaction with the bone marrow microenvironment.
The relevance and significance of this FAIM-Akt-IRF4 signaling axis in MM physiology was evidenced by our knockdown experiment of FAIM expression, which compromised the basal survival of MM cells (Figure 1 ) and their viability even in the presence of IGF-1 (Figure 3 ). This observation is also consistent with the recent demonstration that knockdown of IRF4 expression level 15 or inhibition of PI-3K and Akt signaling 39, 40 could lead to MM cell death as we showed that IRF4 and Akt act in the same pathway and are downstream of FAIM. Moreover, our data also indicated that the knockdown of FAIM further compromised the expression of the survival gene, MCL-1 and the critical plasma cell transcription factor, Blimp-1 (Figure 1 ) in MM cells. Thus, FAIM could present a good target for therapeutic intervention in MM. In further support of this notion, several recent reports also indicated that FAIM could have a role in CD40 signaling 22 and nuclear factor kappa-light-chain-enhancer of activated B cells activation, 18 and all these signaling pathways have been implicated in MM pathology. Hence, targeting FAIM could conceptually cripple these pathways in tandem. A recent study has showed that IL-6 could upregulate IRF4 via c/EBPb activation. 41 In our current study, we found that IL-6 could also induce FAIM expression (Figures 2b  and c) . Hence, it will be interesting to investigate in future if FAIM is involved in IL-6-induced upregulation of IRF4 in MM cells, and if there could be a relationship between FAIM, c/EBPb and IRF4. If this finding is true, then targeting FAIM could also disrupt survival and drug resistance signals resulting from microenvironment interaction mediated not only by IGF-1, but also IL-6, which together had been shown to be important mechanisms that underpins the therapeutic efficacies of novel treatments such as thalidomide, bortezomib and lenalidomide to some extent.
The clinical relevance of FAIM in MM was glimpsed through the analyses of FAIM expression level in primary disease tissues. Interestingly, our analyses indicate that FAIM expression level is markedly increased in symptomatic MM patients compared with normal individuals or patients with premalignant conditions ( Figure 5 High FAIM expression is defined as higher than median expression while low FAIM expression indicates those with lower than median expression.
role in MM. FAIM overexpression had also recently been documented in chronic myeloproliferative disorders 42 suggesting that it could have physiological consequences in other human ailments. More importantly, elevated FAIM expression level is associated with significantly poorer survival outcomes of MM patients receiving current standard treatments such as high-dose chemotherapy and stem cell transplantation or treatment with Bortezomib. The concurrent identification of a poor-risk marker, which itself may be a useful and novel therapeutic target in myeloma will be useful for selection of patients for targeted therapy in myeloma.
